Additional Treatments for Persistent Overt Hypercortisolism in Cushing's Syndrome
STEP 1 — Gather Information
Collect postoperative biochemical tests (24‑h UFC, midnight salivary cortisol, morning serum cortisol) obtained 1–3 months after transsphenoidal surgery; document clinical signs/symptoms of hypercortisolism (weight gain, hypertension, hyperglycemia, skin changes); review postoperative imaging for residual lesion; note prior treatments and comorbidities.
STEP 2 — Rule In / Rule Out
Is there biochemical evidence of persistent overt hypercortisolism (UFC > upper limit of normal or midnight salivary cortisol > normal) accompanied by compatible clinical features? If YES, proceed to Step 3; if NO, consider eucortisolism or hypocortisolism and manage accordingly (no additional anti‑cortisol therapy indicated).
STEP 3 — Classify or Stratify
Determine ACTH dependence: measure plasma ACTH. If ACTH‑suppressed (<5 pg/mL) → adrenal source; if ACTH‑detectable → ACTH‑dependent (Cushing’s disease or ectopic). For ACTH‑dependent disease, assess surgical feasibility (resectable lesion on MRI) and prior radiation; for adrenal source, evaluate for bilateral adrenal hyperplasia or carcinoma.
STEP 4 — Decide
- ACTH‑dependent, resectable lesion → recommend repeat transsphenoidal surgery.
- ACTH‑dependent, not resectable or failed repeat TSS → recommend radiotherapy (conventional or stereotactic) after confirming medical cortisol control, or medical therapy (steroidogenesis inhibitor or receptor antagonist) as bridge.
- ACTH‑suppressed (adrenal source) → recommend bilateral adrenalectomy if feasible; if not, medical therapy to control cortisol while planning definitive therapy.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate medical therapy as definitive treatment when repeat surgery or radiotherapy is curative and feasible; avoid radiation without prior biochemical control to prevent Nelson syndrome; monitor for hypocortisolism after bilateral adrenalectomy and provide lifelong glucocorticoid/mineralocorticoid replacement; watch for hepatotoxicity with ketoconazole and QT prolongation with pasireotide; do not rely solely on symptoms—biochemical confirmation required.
Concrete Clinical Example
A 45‑year‑old woman 2 months post‑TSS for Cushing’s disease has UFC 350 ng/dL (ULN 145), midnight salivary cortisol 1.2 × ULN, persistent facial plethora and hypertension; MRI shows a 6 mm residual pituitary adenoma. ACTH is detectable. She is a surgical candidate → repeat transsphenoidal surgery is recommended.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI:10.1210/jc.2015-1818